UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 27, 2026

60 DEGREES PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware	**001-41719**	**45-2406880**
(State or other jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

1025 Connecticut Avenue NW Suite 1000, Washington, D.C.	**20036**
(Address of registrant's principal executive office)	(Zip code)

(202) 327-5422
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	SXTP	The Nasdaq Stock Market LLC
Warrants, each warrant to purchase one share of Common Stock	SXTPW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On November 27, 2026, 60 Degrees Pharmaceuticals, Inc. (the "Company") received an additional staff determination letter (the "Letter") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it no longer complies with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders' equity for continued listing (the "Stockholders' Equity Requirement"). The Letter noted that the Company's Quarterly Report on Form 10-Q for the period ended September 30, 2026, reported stockholders' equity of $755,911, and that, as of the date of the Letter, the Company does not meet the alternative continued listing standards of a market value of listed securities of at least $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years.

The Letter stated that the Company's non-compliance with the Stockholders' Equity Requirement serves as an additional basis for delisting the Company's securities from Nasdaq, and that the Nasdaq Hearings Panel (the "Panel") will consider this matter in rendering its determination regarding the Company's continued listing on The Nasdaq Capital Market. Pursuant to Nasdaq Listing Rule 5810(d), the Company should present its views with respect to this additional deficiency at its hearing before the Panel, which is currently scheduled for January 7, 2027. If the Company fails to address this deficiency, the Panel will make its determination based on the record presented at the hearing.

The Company intends to present its views and a plan to regain compliance with the Stockholders' Equity Requirement, together with its previously disclosed deficiencies, at the hearing before the Panel. The Company's securities will continue to trade on The Nasdaq Capital Market pending the Panel's decision. There can be no assurance that the Panel will grant the Company's request for continued listing or that the Company will be able to regain compliance with the Stockholders' Equity Requirement or any other applicable Nasdaq listing requirement.

Item 7.01. Regulation FD Disclosure

In accordance with Nasdaq Listing Rule 5810(b), the Company is issuing this Current Report on Form 8-K to publicly disclose receipt of the Nasdaq staff determination letter described above.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

60 DEGREES PHARMACEUTICALS, INC.

Date: November 27, 2026

By: */s/ Geoffrey Dow*
Name: Geoffrey Dow
Title: Chief Executive Officer and President